Crinetics Pharmaceuticals (CRNX) Stock Forecast & Price Target

Compare

735 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CRNX Analyst Ratings

Strong Buy

12 Buy

0 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Crinetics

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CRNX Stock 12 Month Forecast

Average Price Target

$88.64

▲(59.94% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Crinetics Pharmaceuticals in the last 3 months. The average price target is $88.64 with a high forecast of $105.00 and a low forecast of $67.00. The average price target represents a 59.94% change from the last price of $55.42.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"$26","46":"$46","66":"$66","86":"$86","106":"$106"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":105,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$105.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":88.64,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$88.64</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$67.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[26,46,66,86,106],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.55,51.04615384615384,55.54230769230769,60.03846153846153,64.53461538461538,69.03076923076922,73.52692307692308,78.02307692307693,82.51923076923077,87.01538461538462,91.51153846153846,96.00769230769231,100.50384615384615,{"y":105,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.55,49.7876923076923,53.02538461538461,56.26307692307692,59.50076923076923,62.738461538461536,65.97615384615385,69.21384615384616,72.45153846153846,75.68923076923076,78.92692307692307,82.16461538461539,85.40230769230769,{"y":88.64,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.55,48.12307692307692,49.69615384615384,51.26923076923077,52.84230769230769,54.41538461538461,55.988461538461536,57.56153846153846,59.13461538461539,60.707692307692305,62.28076923076923,63.85384615384615,65.42692307692307,{"y":67,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":51.13,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.3,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.78,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.62,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.52,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.88,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.43,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.84,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.3,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.61,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.25,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.55,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$105.00

Average Price Target$88.64

Lowest Price Target$67.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yasmeen Rahimi

Piper Sandler

$97

Buy

75.03%

Upside

Reiterated

01/14/26

Analysts' Top Healthcare Picks: Crinetics Pharmaceuticals (CRNX), Denali Therapeutics (DNLI)

Richard Law CFA

Goldman Sachs

$45→$67

Buy

20.89%

Upside

Reiterated

01/13/26

Crinetics Pharmaceuticals: Phase 2 TouCAHn De‑Risking and Optimized Phase 3 Design Drive Upgrade to Buy and $67 Target

Jonathan Wolleben

Citizens JMP

$108→$105

Buy

89.46%

Upside

Reiterated

01/08/26

Crinetics price target lowered to $105 from $108 at CitizensCrinetics price target lowered to $105 from $108 at Citizens

Maxwell Skor

Morgan Stanley

$80→$87

Buy

56.98%

Upside

Reiterated

01/08/26

Crinetics price target raised to $87 from $80 at Morgan StanleyCrinetics price target raised to $87 from $80 at Morgan Stanley

Leland Gershell

Oppenheimer

$87

Buy

56.98%

Upside

Reiterated

01/06/26

Crinetics Pharmaceuticals (CRNX) Receives a Buy from Oppenheimer

Douglas Tsao

H.C. Wainwright

$81

Buy

46.16%

Upside

Reiterated

01/05/26

Crinetics (CRNX): Robust Atumelnant CAH Data, De-Risked Phase 3, and Strong Execution Underpin Buy Rating

Catherine Novack

JonesTrading

$85→$97

Buy

75.03%

Upside

Reiterated

01/05/26

Crinetics price target raised to $97 from $85 at JonesResearchCrinetics price target raised to $97 from $85 at JonesResearch

Gavin Clark-Gartner

Evercore ISI

$80→$90

Buy

62.40%

Upside

Reiterated

01/05/26

Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (NASDAQ: CRNX) and Exact Sciences (NASDAQ: EXAS)

Cory Jubinville, PhD

LifeSci Capital

$93→$99

Buy

78.64%

Upside

Reiterated

01/05/26

Crinetics Buy Rating: Derisked Atumelnant CAH Program and Outperforming Palsonify Launch Signal Undervalued Shares

Tyler Van Buren

TD Cowen

Buy

―

Reiterated

11/11/25

Buy Rating Justified by Strategic Initiatives and Growth Prospects at Crinetics Pharmaceuticals

Alex Thompson CFA

Stifel Nicolaus

$75

Buy

35.33%

Upside

Reiterated

11/07/25

Stifel Nicolaus Sticks to Its Buy Rating for Crinetics Pharmaceuticals (CRNX)

Joshua Schimmer

Cantor Fitzgerald

$90

Buy

62.40%

Upside

Reiterated

11/06/25

Cantor Fitzgerald Sticks to Its Buy Rating for Crinetics Pharmaceuticals (CRNX)

Joseph Schwartz

Leerink Partners

$80→$88

Buy

58.79%

Upside

Reiterated

09/29/25

Analysts Are Bullish on Top Healthcare Stocks: Avidity Biosciences (RNA), Crinetics Pharmaceuticals (CRNX)

Brian Skorney

Robert W. Baird

$58→$62

Buy

11.87%

Upside

Reiterated

09/26/25

Robert W. Baird Keeps Their Buy Rating on Crinetics Pharmaceuticals (CRNX)

Jessica Fye

J.P. Morgan

$53→$52

Buy

-6.17%

Downside

Reiterated

09/24/25

Crinetics price target lowered to $52 from $53 at JPMorganCrinetics price target lowered to $52 from $53 at JPMorgan

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yasmeen Rahimi

Piper Sandler

$97

Buy

75.03%

Upside

Reiterated

01/14/26

Analysts' Top Healthcare Picks: Crinetics Pharmaceuticals (CRNX), Denali Therapeutics (DNLI)

Richard Law CFA

Goldman Sachs

$45→$67

Buy

20.89%

Upside

Reiterated

01/13/26

Crinetics Pharmaceuticals: Phase 2 TouCAHn De‑Risking and Optimized Phase 3 Design Drive Upgrade to Buy and $67 Target

Jonathan Wolleben

Citizens JMP

$108→$105

Buy

89.46%

Upside

Reiterated

01/08/26

Crinetics price target lowered to $105 from $108 at CitizensCrinetics price target lowered to $105 from $108 at Citizens

Maxwell Skor

Morgan Stanley

$80→$87

Buy

56.98%

Upside

Reiterated

01/08/26

Crinetics price target raised to $87 from $80 at Morgan StanleyCrinetics price target raised to $87 from $80 at Morgan Stanley

Leland Gershell

Oppenheimer

$87

Buy

56.98%

Upside

Reiterated

01/06/26

Crinetics Pharmaceuticals (CRNX) Receives a Buy from Oppenheimer

Douglas Tsao

H.C. Wainwright

$81

Buy

46.16%

Upside

Reiterated

01/05/26

Crinetics (CRNX): Robust Atumelnant CAH Data, De-Risked Phase 3, and Strong Execution Underpin Buy Rating

Catherine Novack

JonesTrading

$85→$97

Buy

75.03%

Upside

Reiterated

01/05/26

Crinetics price target raised to $97 from $85 at JonesResearchCrinetics price target raised to $97 from $85 at JonesResearch

Gavin Clark-Gartner

Evercore ISI

$80→$90

Buy

62.40%

Upside

Reiterated

01/05/26

Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (NASDAQ: CRNX) and Exact Sciences (NASDAQ: EXAS)

Cory Jubinville, PhD

LifeSci Capital

$93→$99

Buy

78.64%

Upside

Reiterated

01/05/26

Crinetics Buy Rating: Derisked Atumelnant CAH Program and Outperforming Palsonify Launch Signal Undervalued Shares

Tyler Van Buren

TD Cowen

Buy

―

Reiterated

11/11/25

Buy Rating Justified by Strategic Initiatives and Growth Prospects at Crinetics Pharmaceuticals

Alex Thompson CFA

Stifel Nicolaus

$75

Buy

35.33%

Upside

Reiterated

11/07/25

Stifel Nicolaus Sticks to Its Buy Rating for Crinetics Pharmaceuticals (CRNX)

Joshua Schimmer

Cantor Fitzgerald

$90

Buy

62.40%

Upside

Reiterated

11/06/25

Cantor Fitzgerald Sticks to Its Buy Rating for Crinetics Pharmaceuticals (CRNX)

Joseph Schwartz

Leerink Partners

$80→$88

Buy

58.79%

Upside

Reiterated

09/29/25

Analysts Are Bullish on Top Healthcare Stocks: Avidity Biosciences (RNA), Crinetics Pharmaceuticals (CRNX)

Brian Skorney

Robert W. Baird

$58→$62

Buy

11.87%

Upside

Reiterated

09/26/25

Robert W. Baird Keeps Their Buy Rating on Crinetics Pharmaceuticals (CRNX)

Jessica Fye

J.P. Morgan

$53→$52

Buy

-6.17%

Downside

Reiterated

09/24/25

Crinetics price target lowered to $52 from $53 at JPMorganCrinetics price target lowered to $52 from $53 at JPMorgan

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Crinetics Pharmaceuticals

3 Months

xxx

Success Rate

14/15 ratings generated profit

Average Return

+23.45%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 93.33% of your transactions generating a profit, with an average return of +23.45% per trade.

1 Year

Douglas TsaoH.C. Wainwright

Success Rate

18/23 ratings generated profit

Average Return

+51.25%

reiterated a buy rating 11 days ago

Copying Douglas Tsao's trades and holding each position for 1 Year would result in 78.26% of your transactions generating a profit, with an average return of +51.25% per trade.

2 Years

xxx

Success Rate

15/15 ratings generated profit

Average Return

+34.11%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +34.11% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CRNX Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CRNX has received 20 Buy Ratings, 17 Hold Ratings, and 0 Sell Ratings. CRNX average Analyst price target in the past 3 months is 88.64.

Each month's total comprises the sum of three months' worth of ratings.

CRNX Financial Forecast

CRNX Earnings Forecast

Next quarter’s earnings estimate for CRNX is -$1.34 with a range of -$1.52 to -$1.09. The previous quarter’s EPS was -$1.38. CRNX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year CRNX has Performed in-line its overall industry.

CRNX Sales Forecast

Next quarter’s sales forecast for CRNX is $4.15M with a range of $2.10M to $8.00M. The previous quarter’s sales results were $143.00K. CRNX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year CRNX has Performed in-line its overall industry.

CRNX Stock Forecast FAQ

What is CRNX’s average 12-month price target, according to analysts?

Based on analyst ratings, Crinetics Pharmaceuticals’s 12-month average price target is 88.64.

What is CRNX’s upside potential, based on the analysts’ average price target?

Crinetics Pharmaceuticals has 59.94% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CRNX a Buy, Sell or Hold?

Crinetics Pharmaceuticals has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.

What is Crinetics Pharmaceuticals’s price target?

The average price target for Crinetics Pharmaceuticals is 88.64. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $105.00 ,the lowest forecast is $67.00. The average price target represents 59.94% Increase from the current price of $55.42.

What do analysts say about Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of CRNX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Crinetics Pharmaceuticals (CRNX) Stock Forecast & Price Target

CRNX Analyst Ratings

CRNX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Crinetics Pharmaceuticals

CRNX Analyst Recommendation Trends

CRNX Financial Forecast

CRNX Earnings Forecast

CRNX Sales Forecast

CRNX Stock Forecast FAQ

Detailed List of Analyst Forecasts